Skip to main content
Top
Published in: International Urology and Nephrology 3/2007

01-09-2007 | Original Article

Cytomegalovirus disease with Guillain–Barré syndrome in a cadaver renal allograft recipient: cause or coincidence

Authors: Sai Ram R. Keithi-Reddy, Rajasekhara M. Chakravarthi, Shaista M. Hussaini, Rohini R. Venkatapuram, J. M. K. Murthy

Published in: International Urology and Nephrology | Issue 3/2007

Login to get access

Abstract

Anecdotal reports of acute inflammatory demyelinating polyneuropathy (Guillain–Barré syndrome) with cytomegalovirus (CMV) suggested as the etiological agent have been described in transplant recipients with poor prognosis. We describe a 48-year-old man, a cadaveric renal allograft recipient on cyclosporine, mycophenolate mofetil and prednisolone, who developed febrile illness with unexplained anemia followed by progressive weakness of the upper and lower limbs. He was diagnosed as a case of Guillain–Barré syndrome (GBS). His CMV serology was positive by polymerase chain reaction (PCR). We treated him with both gancyclovir and intravenous immunoglobulins within a week of the onset of GBS and observed rapid recovery. Thus, search for CMV is warranted in transplant patients presenting with GBS, as early initiation of treatment with gancyclovir and immunoglobulins can help expedite recovery.
Literature
1.
go back to reference van der Meche F Schmitz GPI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326(17):1123–1129PubMedCrossRef van der Meche F Schmitz GPI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326(17):1123–1129PubMedCrossRef
2.
go back to reference Bulsara KR, Baron PW Tuttle-Newhall JE et al (2001) Guillain-Barre syndrome in organ and bone marrow transplant patients. Transplantation 71(8):1169–1172PubMedCrossRef Bulsara KR, Baron PW Tuttle-Newhall JE et al (2001) Guillain-Barre syndrome in organ and bone marrow transplant patients. Transplantation 71(8):1169–1172PubMedCrossRef
3.
go back to reference Rodriguez V, Kuehnle I Heslop HE et al (2002) Guillain-Barre syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 29(6):515–751PubMedCrossRef Rodriguez V, Kuehnle I Heslop HE et al (2002) Guillain-Barre syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 29(6):515–751PubMedCrossRef
4.
go back to reference El-Sabrout RA, Radovancevic B Ankoma-Sey V et al (2001) Guillain-Barre syndrome after solid organ transplantation. Transplantation 71(9):1311–1316PubMedCrossRef El-Sabrout RA, Radovancevic B Ankoma-Sey V et al (2001) Guillain-Barre syndrome after solid organ transplantation. Transplantation 71(9):1311–1316PubMedCrossRef
5.
go back to reference Visser LH, van der Meche FG Meulstee J et al (1996) Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group Neurology 47(3):668–673 Visser LH, van der Meche FG Meulstee J et al (1996) Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group Neurology 47(3):668–673
6.
go back to reference Hernandez-Boluda JC, Lis MJ Goterris R et al (2005) Guillain-Barre syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 7(2):93–96PubMedCrossRef Hernandez-Boluda JC, Lis MJ Goterris R et al (2005) Guillain-Barre syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 7(2):93–96PubMedCrossRef
7.
go back to reference Asbury A Cornblath KDR (1990) Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27Suppl:S21–S24PubMedCrossRef Asbury A Cornblath KDR (1990) Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27Suppl:S21–S24PubMedCrossRef
8.
go back to reference Ponticelli CM Campise R (2005) Neurological complications in kidney transplant recipients. J Nephrol 18(5):521–528PubMed Ponticelli CM Campise R (2005) Neurological complications in kidney transplant recipients. J Nephrol 18(5):521–528PubMed
10.
go back to reference Wen PY, Alyea EP Simon D et al (1997) Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 49(6):1711–1714PubMed Wen PY, Alyea EP Simon D et al (1997) Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 49(6):1711–1714PubMed
11.
go back to reference Perry A, Mehta J Iveson T et al (1994) Guillain-Barre syndrome after bone marrow transplantation. Bone Marrow Transplant 14(1):165–167PubMed Perry A, Mehta J Iveson T et al (1994) Guillain-Barre syndrome after bone marrow transplantation. Bone Marrow Transplant 14(1):165–167PubMed
12.
go back to reference Hartung HP, van der Meche FG Pollard JD (1998) Guillain-Barre syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 11(5):497–513PubMedCrossRef Hartung HP, van der Meche FG Pollard JD (1998) Guillain-Barre syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 11(5):497–513PubMedCrossRef
13.
go back to reference Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 1(1):29–37PubMedCrossRef Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 1(1):29–37PubMedCrossRef
14.
go back to reference Hartung HP, Pollard JD Harvey GK et al (1995) Immunopathogenesis and treatment of the Guillain-Barre syndrome–Part II. Muscle Nerve 18(2):154–164PubMedCrossRef Hartung HP, Pollard JD Harvey GK et al (1995) Immunopathogenesis and treatment of the Guillain-Barre syndrome–Part II. Muscle Nerve 18(2):154–164PubMedCrossRef
15.
go back to reference Susuki K, Odaka M Mori M et al (2004) Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry. Neurology 62(6):949–956PubMed Susuki K, Odaka M Mori M et al (2004) Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry. Neurology 62(6):949–956PubMed
16.
go back to reference Visser LH, Schmitz PI Meulstee J et al (1999) Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group Neurology 53(3):598–604 Visser LH, Schmitz PI Meulstee J et al (1999) Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group Neurology 53(3):598–604
Metadata
Title
Cytomegalovirus disease with Guillain–Barré syndrome in a cadaver renal allograft recipient: cause or coincidence
Authors
Sai Ram R. Keithi-Reddy
Rajasekhara M. Chakravarthi
Shaista M. Hussaini
Rohini R. Venkatapuram
J. M. K. Murthy
Publication date
01-09-2007
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2007
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-007-9197-7

Other articles of this Issue 3/2007

International Urology and Nephrology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine